

## 2010 Casefinding List: Short Version

Comprehensive ICD-9-CM Casefinding Code List for Reportable Tumors (Effective Date: 1/1/2010)	
ICD-9-CM Code^	Explanation of Code
140.0 – 209.36	Malignant Neoplasms
209.70 – 209.79	Secondary neuroendocrine tumors
225.0 – 225.9	Benign neoplasm of brain and spinal cord neoplasm
227.3 – 227.4	Benign neoplasm of pituitary gland, craniopharyngeal duct (pouch) and pineal gland
227.9	Benign neoplasm; endocrine gland, site unspecified
228.02	Hemangioma; of intracranial structures
228.1	Lymphangioma, any site
230.0 – 234.9	Carcinoma in situ*
236.0	Endometrial stroma, low grade
237.0 – 237.9	Neoplasm of uncertain behavior [borderline] of endocrine glands and nervous system
238.4	Polycythemia vera
238.6 – 238.79	Other lymphatic and hematopoietic tissues
239.6 – 239.89	Neoplasms of unspecified nature
273.2	Other paraproteinemias
273.3	Macroglobulinemia
288.3	Eosinophilia
288.4	Hemophagocytic syndromes
795.06	Papanicolaou smear of cervix with cytologic evidence of malignancy
795.16	Papanicolaou smear of vagina with cytologic evidence of malignancy
796.76	Papanicolaou smear of anus with cytologic evidence of malignancy
V10.0 – V10.91	Personal history of malignancy
V12.41	Personal history of benign neoplasm of the brain

The following codes are not reportable per se, but they should alert registrars to look for the first malignant neoplasm associated with these codes.

## Supplementary List #1-ICD-9-CM Codes that Should Be Followed by or Associated with a Neoplasm Code

ICD-9-CM Code^	Explanation of Code
258.02 – 258.03	Multiple endocrine neoplasia (MEN) type IIA and IIB
285.22	Anemia in neoplastic disease
289.83	Myelofibrosis (NOS) (9961/3)
338.3	Neoplasm related pain (acute, chronic); Cancer associated pain
511.81	Malignant pleural effusion (code first malignant neoplasm if known).
789.51	Malignant ascites (code first malignant neoplasm if known).

Exclusions: Basal/Squamous cell carcinoma of skin, except of genitalia, and \*in situ carcinoma of cervix uteri and PIN are NOT reportable. Note: VIN 3, VAIN 3, AIN 3 (squamous intraepithelial neoplasia Grade 3) and, juvenile astrocytoma, pilocytic astrocytoma, and piloid astrocytoma are reportable to the Oregon State Cancer Registry.

NOTE: Cases with these codes should be screened as registry time allows. These are neoplasm-related secondary conditions for which there should also be a primary diagnosis of a reportable neoplasm.

Supplementary List #2-ICD-9-CM Code List to Screen for Cancer Cases Not Identified by Other Codes (Effective Date: 1/1/2010)	
ICD-9-CM Code^	Explanation of Code
<b>042</b>	Acquired Immunodeficiency Syndrome (AIDS)
<b>079.4</b>	Human papillomavirus
<b>079.50 – 079.59</b>	Retrovirus (HTLV, types I, II and 2)
<b>209.40 – 209.69</b>	Benign carcinoid tumors
<b>210.0 – 229.9</b>	Benign neoplasms (except for 225.0-225.9, 227.3, 227.4, 227.9, 228.02, and 228.1, which are listed in the Reportable list)
<b>235.0 – 236.6, 238.0-239.9</b>	Neoplasms of uncertain behavior (except for 236.0, 238.4, 238.6, 238.71-238.79, 239.6, 239.7, 239.81 and 239.89, which are listed in the Reportable list)
<b>253.6</b>	Syndrome of inappropriate secretion of antidiuretic hormone
<b>259.2, 259.8</b>	Other Endocrine disorders
<b>273.0 – 273.1, 273.9</b>	Disorders of plasma protein metabolism
<b>275.42</b>	Hypercalcemia
<b>277.88</b>	Tumor lysis syndrome following antineoplastic drug therapy
<b>279.00, 279.02 – 279.06</b>	Disorders involving the immune mechanism
<b>279.10, 279.12-279.13</b>	Deficiency of cell-mediated immunity
<b>279.2 – 279.9</b>	Combined immunity deficiency
<b>284.81 – 284.9</b>	Other and unspecified aplastic anemias
<b>285.0, 285.3</b>	Other and unspecified anemias
<b>288.03</b>	Drug induced neutropenia
<b>289.89</b>	Other specified diseases of blood and blood-forming organs
<b>323.81</b>	Encephalomyelitis; specified cause NEC
<b>379.59</b>	Opsoclonia
<b>528.01</b>	Mucositis due to antineoplastic therapy
<b>630</b>	Hydatidiform Mole
<b>686.01</b>	Pyoderma gangrenosum
<b>695.89</b>	Sweet's syndrome
<b>701.2</b>	Acanthosis nigricans
<b>710.3 – 710.4</b>	Diseases of connective tissue
<b>785.6</b>	Enlargement of lymph nodes
<b>790.93</b>	Elevated prostate specific antigen [PSA]
<b>795.8</b>	Abnormal tumor markers; Elevated tumor associated antigens [TAA]; Elevated tumor specific antigens [TSA]; Excludes: Elevated prostate specific antigen [PSA] (790.93)
<b>795.81 – 795.89</b>	Abnormal tumor markers
<b>999.31</b>	Infection due to central venous catheter (porta-cath)
<b>999.81</b>	Extravasation of vesicant chemotherapy
<b>E879.2</b>	Adverse effect of radiation therapy
<b>E930.7</b>	Adverse effect of antineoplastic therapy
<b>E933.1</b>	Adverse effect of immunosuppressive drugs
<b>V07.31, V07.39</b>	Other prophylactic chemotherapy
<b>V07.8</b>	Other specified prophylactic measure

<b>V12.72</b>	History of colonic polyps
<b>V15.3</b>	Irradiation: previous exposure to therapeutic or ionizing radiation
<b>V42.81 – V42.82</b>	Organ or tissue replaced by transplant, Bone marrow transplant
<b>V51.0</b>	Encounter for breast reconstruction following mastectomy
<b>V52.4</b>	Breast prosthesis and implant
<b>V54.2</b>	Aftercare for healing pathologic fracture
<b>V58.0 – V58.12</b>	Encounter for radiation and chemotherapy
<b>V58.42</b>	Aftercare following surgery for neoplasm
<b>V66.1 – V66.2</b>	Convalescence following radiotherapy and/or chemotherapy
<b>V67.1 – V67.2</b>	Radiation and chemotherapy follow up
<b>V71.1</b>	Observation for suspected malignant neoplasm
<b>V76.0 – V76.9</b>	Special screening for malignant neoplasm
<b>V78.0 – V78.9</b>	Special screening for disorders of blood and blood-forming organs
<b>V82.71</b>	Screening for genetic disease carrier status
<b>V82.79</b>	Other genetic screening
<b>V82.89</b>	Genetic screening for other specified conditions
<b>V82.9</b>	Genetic screening for unspecified condition
<b>V84.01 – V84.09</b>	Genetic susceptibility to malignant neoplasm
<b>V84.81</b>	Genetic susceptibility to multiple endocrine neoplasia [MEN]
<b>V86.0 – V86.1</b>	Estrogen receptor status
<b>V87.41</b>	Personal history of antineoplastic chemotherapy

<sup>^</sup> *International Classification of Diseases, Ninth Revision, Clinical Modification, 2009.*